Inhibition of interferon-gamma and interleukin-2 production from lymphocytes stimulated with food antigens by an anti-allergic drug, Tranilast, in patients with food-sensitive atopic dermatitis

Biotherapy. 1994;8(1):19-22. doi: 10.1007/BF01878117.

Abstract

N(3',4'-dimethoxycinnamoyl) anthranilic acid (Tranilast) inhibits antibody-mediated hypersensitivity reactions, and is an effective drug for patients with bronchial asthma or allergic rhinitis. Interferon-gamma (IFN-gamma) production of ovalbumin (OA)-stimulated peripheral blood mononuclear cells (PBMCs) from hen's egg-sensitive patients with atopic dermatitis (AD) was significantly higher than those of healthy controls. Tranilast inhibited this IFN-gamma production. Moreover, interleukin-2 (IL-2) production of OA-stimulated PBMCs from hen's egg-sensitive patients with AD was also inhibited by Tranilast. Our results suggest that Tranilast can be used to the patients with food sensitive AD.

Publication types

  • Clinical Trial

MeSH terms

  • Anti-Allergic Agents / pharmacology*
  • Cells, Cultured
  • Child, Preschool
  • Dermatitis, Atopic / immunology
  • Dermatitis, Atopic / metabolism
  • Double-Blind Method
  • Food Hypersensitivity / immunology*
  • Humans
  • Infant
  • Interferon-gamma / biosynthesis*
  • Interleukin-2 / biosynthesis*
  • Lymphocytes / metabolism*
  • Ovalbumin / immunology*
  • ortho-Aminobenzoates / pharmacology*

Substances

  • Anti-Allergic Agents
  • Interleukin-2
  • ortho-Aminobenzoates
  • Interferon-gamma
  • Ovalbumin
  • tranilast